JPRN-UMIN000012263已完成3 期
A Multinational, Randomized, Phase III Study of XELIRI with/without Bevacizumab versus FOLFIRI with/without Bevacizumab as Second-line Therapy in Patients with Metastatic Colorectal Cancer. - Asian XELIRI Project (AXEPT): non-inferiority study of FOLFIRI with/without Bevacizumab vs. XELIRI with/without Bevacizumab as 2nd-line therapy in patients with mCRC
PO Epidemiological and Clinical Research Information Network (ECRIN)0 个研究点目标入组 600 人开始时间: 2013年11月11日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 600
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1)Contraindications of each protocol drugs 2)History of other malignancy with a disease-free survival<5 years 3)Radiological evidence of brain tumor or brain metastases 4)Active infection including hepatitis 5)Previous treatment with irinotecan hydrochloride 6)Pregnant or lactating females, and males and females unwilling to use contraception 7)Requires continuous treatment with systemic steroids 8)Psychiatric disability that would preclude study compliance 9)Otherwise determined by the investigator to be unsuitable for participation in the study <In case of combination with Bevacizumab> 10)Concurrent or recent (within 1 year before enrollment) gastrointestinal perforation 11)Unhealed wound, gastrointestinal ulcer, or traumatic fracture 12)Current or recent(within 1 year before enrollment)thromboembolism or cerebrovascular disease 13)Uncontrolled hypertension 14)Urine dipstick for proteinuria>+2
研究者
相似试验
进行中（未招募）
不适用
Immunogenicity, safety and reactogenicity study of GlaxoSmithKline (GSK) Biologicals’ Hib-MenCY-TT vaccine compared to monovalent Hib vaccine in healthy infants at 2, 4, 6, and 12 to 15 months of age.Invasive disease caused by Haemophilus type b and Neisseria meningitidis serogroups C and YMedDRA version: 18.0Level: LLTClassification code 10028910Term: Neisseria meningitides meningitisSystem Organ Class: 100000004862MedDRA version: 18.0Level: LLTClassification code 10051931Term: Neisseria infection NOSSystem Organ Class: 100000004862EUCTR2005-002352-18-Outside-EU/EEAGlaxoSmithKline Biologicals4,441
进行中（未招募）
1 期
A Phase III study to assess the lot-to-lot consistency of GSK’s investigational RSV maternal vaccine and the immune response and safety of RSV maternal vaccine when given alone or co-administered with GSK’s influenza D-QIV vaccine in healthy non-pregnant women.Healthy volunteers (prevention of RSV-associated lower respiratory tract illnesses (LRTIs))EUCTR2021-000357-26-FIGlaxoSmithKline Biologicals1,541
进行中（未招募）
1 期
Efficacy and Safety of Selumetinib in Adults with NF1 who have Symptomatic, Inoperable Plexiform Neurofibromaseurofibromatosis Type 1 (NF1) with Symptomatic, Inoperable Plexiform Neurofibromas (PN)MedDRA version: 20.0Level: LLTClassification code 10029270Term: Neurofibromatosis, type 1 (von Recklinghausen's disease)System Organ Class: 100000004850EUCTR2020-005607-39-PLAstraZeneca AB146
招募中
1 期
Efficacy and Safety of Selumetinib in Adults with NF1 who have Symptomatic, Inoperable Plexiform Neurofibromas.eurofibromatosis Type 1 (NF1) with Symptomatic, Inoperable Plexiform Neurofibromas (PN).CTIS2023-507336-20-00Astrazeneca AB145
进行中（未招募）
1 期
Efficacy and Safety of Selumetinib in Adults with NF1 who have Symptomatic, Inoperable Plexiform Neurofibromaseurofibromatosis Type 1 (NF1) with Symptomatic, Inoperable Plexiform Neurofibromas (PN)MedDRA version: 20.0Level: LLTClassification code 10029270Term: Neurofibromatosis, type 1 (von Recklinghausen's disease)System Organ Class: 100000004850EUCTR2020-005607-39-ESAstraZeneca AB146